SFI Centre for Advanced Materials and BioEngineering Research
Follow
MX-MAP Towards MXenes’ biomedical applications by high-dimensional immune MAPping
Innovative biomedical applications of MXenes nanomaterials MXenes are a new family of recently discovered 2D transition metal carbides, carbonitrides, and nitrides. The immune characterisation of the new materials on the basis of their physical-chemical and immunological properties will open up perspectives for the development of new therapeutic applications of nanomaterials in tissue engineering, cancer therapy, as antibacterial agents, and as immunomodulators. Funded by the Marie Skłodowska-Curie Actions programme, the MX-MAP project will develop key strategies for MXene medical applications. The long-term goal of MX-MAP is to create a pipeline using new MXene nanomaterials for the qualitative and quantitative assessment of immunological compatibility in biomedical applications. This international research/training programme aims to support the career development of young researchers with an interdisciplinary vision of science.
The long-term goal of MX-MAP is to develop a functional pipeline for the immune characterization of new 2D nanomaterials of MXene family, for the qualitative and quantitative assessment of the human immune compatibility and immune activity towards biomedical applications. The immune characterization of the tested materials on the basis of intrinsic physical-chemical and immunological properties, through the combination of the most innovative technologies such as single-cell mass cytometry (CyTOF), will open breakthrough perspectives for the development of new therapeutic approaches applying nanomaterials as immunomodulators, scaffolds for tissue engineering, cancer therapy, and antibacterial agents.
MX-MAP will develop key chemistry and immune-based strategies for MXene medical applications. The implication of this project extends beyond the specific nanoscience program greatly advancing the engineering process of 2D materials and their use in biomedicine.
This project is an MSCA staff exchange programme with a start date of 1st November 2022 and a budget of €1,389,200.
AMBER Researcher & Project Partner: Valeria Nicolosi
AMBER has a strong emphasis on collaboration. Central to AMBER’s research remit are collaborative projects performed with industry partners, and working with academic, industry and wider stakeholder on international and national research programmes.
Get in touch